SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as traders anticipate potential catalysts ahead of upcoming earnings, with some pointing to renewed interest from Michael Burry and the possible return of Roaring Kitty. The community is buzzing about potential short squeezes and the company's strong cash position, while also debating the impact of meme stock hype versus fundamental value. Discussions include speculation on share buybacks and the potential for a significant market move.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is experiencing a surge driven by news of recent global partnerships, sparking significant community interest. The stock's low float is contributing to extreme volatility and discussions of a potential short squeeze, with some traders drawing parallels to other high-momentum stocks. Community members are actively debating entry and exit strategies amidst the rapid price fluctuations.

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Cel-Sci Corp.

Cel-Sci Corp

CVM is trending as community members analyze its potential regulatory path in Saudi Arabia and discuss the company's financial positioning. The stock's upward momentum and potential catalysts are key talking points, alongside debates on market manipulation and the validity of past clinical trial results. Some are expressing concerns around dilution and timeline delays.

On Solana, there’s only one way to have a true multi million dollar runner…. we all have to buy the same coin.

Same Coin

The crypto, $SAME, is gaining attention as a community-driven initiative focused on coordinated buying. Social media discussions suggest the coin was recently listed on ST, generating excitement. The core idea revolves around collective action, with many users echoing the sentiment to "buy the SAME coin."

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as its community rallies around the OG meme coin, emphasizing its strong community and potential for growth in the meme culture space. Discussions highlight the project's active development, expanding social media presence, and the unique appeal of its meme-based identity. The community is expressing excitement about upcoming catalysts and the potential for RAGE to lead the next memecoin cycle.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

$4CHAN is trending as community members rally around its memetic origins and potential for significant gains, with some calling it the '$BTC of memecoins.' Conversations revolve around accumulating more tokens, dismissing negative sentiment, and anticipating a substantial market surge, highlighting its roots in internet culture and meme creation.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to a recently announced Zacks Small Cap Research report with a notably high price target, sparking excitement among investors. The community is actively discussing the potential of the company's drug pipeline and its recent Frunexian acquisition. Some concerns are being raised about executive compensation and potential dilution, while others see a compelling opportunity given the company's partnerships and pipeline progress.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

Recent market volatility and concerns about stretched valuations, particularly in tech, have put downward pressure on the DIA. A potential AI bubble and a shift in market sentiment are being debated by investors, while some point to overbought conditions and historical patterns suggesting further declines. Some traders are closely watching the Dow's performance relative to other indices, like the QQQ, for potential trading signals.

Copart, Inc. engages in the provision of online auctions and vehicle remarketing services. The firm offers vehicle sellers a full range of services to process and sell vehicles primarily over the internet through Virtual Bidding Third Generation Internet auction-style sales technology. It sells vehicles principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, exporters and at certain locations, and the public. The company’s services include online seller access, salvage estimation services, estimating services, end-of-life vehicle processing, virtual insured exchange, transportation services, vehicle inspection stations, on-demand reporting, DMV processing, and vehicle processing programs. It operates through the United States and International segments. The company was founded by Willis J. Johnson in 1982 and is headquartered in Dallas, TX.

Copart, Inc.

Copart, Inc. is trending as investors assess its growth potential amid discussions around rising operating expenses and competition. The community is weighing strong earnings, analyst ratings, and historical resilience against softening used car demand and potential market share losses. AI's increasing role in vehicle assessment, fraud detection, and customer service is also being discussed as a potential catalyst.

Chagee Holdings Ltd. engages in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment, and other supplies. Its products include tea latte, teapuccino, iced oriental tea, teaspresso, and other creative tea drinks. The company was founded by Jun Jie Zhang in June 2017 and is headquartered in Shanghai, China.

Chagee Holdings Ltd. - ADR

Chagee ($CHA) is trending due to mixed sentiment around recent earnings and an upcoming dividend, sparking debates about its current valuation. The stock's volatility, coupled with its China-based IPO status, has investors weighing potential risks and rewards. Community members are actively discussing analyst ratings, potential for a short squeeze, and expansion plans.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimates for Vivani Medical Boosted by Analyst

Vivani Medical, Inc. (NASDAQ:VANI - Free Report) - Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Vivani Medical in a research report issued on...

Vivani Medical (NASDAQ:VANI) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen raised Vivani Medical to a "sell" rating in a research report on Saturday...

Gregg Williams Purchases 1,737,764 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams purchased 1,737,764 shares of Vivani Medical stock in a transaction on Saturday, November 15th. The stock was purchased at...

Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,737,764 Shares

Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 1,737,764 shares of Vivani Medical stock in a transaction dated Saturday, November 15th. The shares were bought...

Vivani Medical (NASDAQ:VANI) Upgraded to Hold at Zacks Research

Zacks Research raised shares of Vivani Medical from a "strong sell" rating to a "hold" rating in a report on Wednesday...

Vivani Medical (NASDAQ:VANI) Issues Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.12...

Vivani Medical (VANI) Projected to Post Earnings on Wednesday

Vivani Medical (NASDAQ:VANI) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...

Vivani Medical, Inc. (VANI), on Wednesday, <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.vivani.com/investors/news-events/press-releases/detail/188/vivani-medical-announces-positive-preclinical-weight-loss">announced</a> promising preclinical data for its semaglutide implant in development for weight management in overweight patients.NPM-139 is a small, subdermal semaglutide implant. Semaglutide is the active ingredient in popular weight-loss drugs such as Ozempic or Wegovy.Vivani Medical CEO Adam Mendelsohn said products containing semaglutide generated $25 billion in 2024, and demand for these products continues to soar.“Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes,” he said.The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant.NPM-139 is being initially developed as a twice-yearly implant but has the potential benefit of once-yearly administration, the company said.The company also said it recently successfully implanted an initial group of human subjects with NPM-115, a miniature, ultra long-acting exenatide implant aimed at overweight persons.Data from the study of NPM-115 is expected to be available mid-2025. The study is also expected to pave the way for the development of NPM-139, the company said.On Stocktwits, retail sentiment about Vivani rose from ‘bullish’ to ‘extremely bullish’ territory while message volume jumped from ‘low’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:649/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_26_at_1_56_56_PM_png_deb5769989.webp" alt="VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits" width="649" height="150"><figcaption>VANI's Sentiment Meter and Message Volume as of 1:55 p.m. ET on March 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits commended the company’s idea of implants, taking out the need for daily pills or injections.<stembedurl>https://stocktwits.com/ZabDad/message/609254484</stembedurl>Brokerage H.C. Wainwright said on Wednesday that the preclinical data validates the versatility of the company’s proprietary NanoPortal implant technology while reiterating a ‘Buy’ rating on the shares with a price target of $4.A Stocktwits user, however, highlighted the company’s low cash. As of Sept. 30, 2024, Vivani had cash, cash equivalents, and restricted cash totaling $21 million.<stembedurl>https://stocktwits.com/Earl40/message/609298832</stembedurl><a href="https://stocktwits.com/symbol/VANI">VANI shares</a> traded nearly 2% higher on Wednesday afternoon. The stock is down over 6% this year and by over 40% in the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-spins-off-micromobility-business-into-new-company-also/chJbT8iRb3m">Rivian Spins Off Micromobility Business Into New Company ‘Also’: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A tape measure lies on a scale while a young woman buries her head in her hands in the background. (Photo by Pia Bayer/picture alliance via Getty Images)

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that received a sham implant. 

Equity

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

Vivani Medical, Inc. (NASDAQ: VANI) (the Company or Vivani), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

Vivani Medical, Inc. (Nasdaq: VANI) (Vivani or the Company), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the third quarter...

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

VANI
Vivani Medical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VANI News

VANIVivani Medical Inc